Atrial Fibrillation Paroxysmal

Cardiovascular
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Pulse Biosciences
Pulse BiosciencesCA - Hayward
1 program
CellFX nsPFA Cardiac Catheter SystemN/A1 trial
Active Trials
NCT07018596Not Yet Recruiting215Est. Jan 2027

Trial Timeline

Clinical trial activity over time

2026
2027
Pulse BiosciencesCellFX nsPFA Cardiac Catheter System

Clinical Trials (1)

Total enrollment: 215 patients across 1 trials

NCT07018596Pulse BiosciencesCellFX nsPFA Cardiac Catheter System

NS-PFA Catheter Ablation of Paroxysmal Atrial Fibrillation With the Pulse Biosciences CellFX System

Start: Jan 2026Est. completion: Jan 2027215 patients
N/ANot Yet Recruiting

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space